The predictive value of serum HDAC3 and LOXL2 for recurrence of atrial fibrillation in patients with persistent atrial fibrillation after radiofrequency ablation

doi:10.11958/20253150

Abstract

Abstract:

Objective To analyze the predictive value of serum histone deacetylase 3 (HDAC3) and lysyl oxidase like protein 2 (LOXL2) levels in patients with persistent atrial fibrillation for artial fibrillation recurrence one year after radiofrequency ablation. Methods A total of 200 patients with persistent atrial fibrillation treated in our hospital were served as the disease group, and 132 healthy individuals of the same age during the same period were selected as the healthy group. Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of serum HDAC3 and LOXL2 before and after surgery in the two groups, and other relevant clinical indicators were collected. Patients were assigned into the non recurrence group (125 cases) and the recurrence group (75 cases) based on their recurrence status within one year. Multivariate Logistic regression model was used to analyze factors influencing the recurrence within one year in patients of the disease group. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of serum HDAC3 and LOXL2 levels for recurrence of atrial fibrillation in patients within one year. Results The postoperative serum HDAC3 and LOXL2 levels were prominently lower in the disease group than those before surgery (P<0.05). The serum levels of HDAC3 and LOXL2 were higher in the recurrence group than those in the non-recurrence group (P<0.05). The high levels of HDAC3 and LOXL2 were risk factors affecting the recurrence of atrial fibrillation in patients (P<0.05). The area under the curve (AUC) values of serum HDAC3 and LOXL2 alone and their combination for predicting recurrence of atrial fibrillation in patients in the disease group were 0.833 (95%CI: 0.774-0.882), 0.829 (95%CI: 0.770-0.879) and 0.907 (95%CI: 0.858-0.943), respectively. The combined prediction was superior to the individual predictions (Z_{combination-HDAC3}=3.384, Z_{combination-LOXL2}=3.438, P<0.05). Conclusion The elevated serum levels of HDAC3 and LOXL2 are factors influencing the recurrence of atrial fibrillation in patients, and both are predictive factors that affect recurrence of atrial fibrillation in patients one year after radiofrequency ablation.

Key words: atrial fibrillation, radiofrequency ablation, histone deacetylases, recurrence, lysyl oxidase like protein 2

CLC Number:

R541.75

Figures/Tables 6

References 20

[1]	YUE X, ZHOU L, ZHAO C. Integrated management of persistent atrial fibrillation[J]. Biomedicines, 2025, 13(1):91. doi:10.3390/biomedicines13010091.
[2]	邱原, 张昊, 梁兆光. 射频消融术治疗持续性心房颤动的评价[J]. 国际心血管病杂志, 2023, 50(1):34-37.
	QIU Y, ZHANG H, LIANG Z G. The effect of radiofrequency catheter ablation for treating persistent atrial fibrillation[J]. Int J Cardiovasc Dis, 2023, 50(1):34-37. doi:10.3969/j.issn.1673-6583.2023.01.009.
[3]	张颖, 郝晓一, 曹艳梅. 经食管超声心动图评价左心耳功能对房颤射频消融术后复发的预测价值[J]. 医学影像学杂志, 2025, 35(1):49-52.
	ZHANG Y, HAO X Y, CAO Y M. Evaluation of left atrial appendage function by transesophageal echocardiography for predicting recurrence of atrial fibrillation after radiofrequency ablation[J]. J Med Imaging, 2025, 35(1):49-52. doi:10.20258/j.cnki.1006-9011.2025.01.012.
[4]	ZHANG D, HU X, LI J, et al. Converse role of class I and class IIa HDACs in the progression of atrial fibrillation[J]. J Mol Cell Cardiol, 2018, 125:39-49. doi:10.1016/j.yjmcc.2018.09.010.
[5]	WU Y, CAN J, HAO S, et al. LOXL2 Inhibitor attenuates angiotensin II-induced atrial fibrosis and vulnerability to atrial fibrillation through inhibition of transforming growth factor beta-1 Smad2/3 pathway[J]. Cerebrovasc Dis, 2022, 51(2):188-198. doi:10.1159/000518526.
[6]	杨子琪, 朱泽宇, 罗启余, 等. 《2023 ACC/AHA/ACCP/HRS心房颤动诊断和管理指南》解读[J]. 中国胸心血管外科临床杂志, 2024, 31(5):654-666.
	YANG Z Q, ZHU Z Y, LUO Q Y, et al. Interpretation of the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation[J]. Chin J Clin Thorac Cardiovasc Surg, 2024, 31(5):654-666. doi:10.7507/1007-4848.202402044.
[7]	高贝贝, 卞王露, 李承宗, 等. 持续性心房颤动射频消融术后复发的危险因素及其风险预测评估[J]. 徐州医科大学学报, 2021, 41(9):651-655.
	GAO B B, BIAN W L, LI C Z, et al. Risk factors and risk prediction for the recurrence of persistent atrial fibrillation after radiofrequency catheter ablation[J]. J Xuzhou Med Univ, 2021, 41(9):651-655. doi:10.3969/j.issn.2096-3882.2021.09.006.
[8]	HE R, HE Z, ZHANG T, et al. HDAC3 in action:expanding roles in inflammation and inflammatory diseases[J]. Cell Prolif, 2025, 58(1):e13731. doi:10.1111/cpr.13731.
[9]	YU H, LIU S, WANG S, et al. The involvement of HDAC3 in the pathogenesis of lung injury and pulmonary fibrosis[J]. Front Immunol, 2024, 15:1392145. doi:10.3389/fimmu.2024.1392145.
[10]	QIU Z, MING H, LEI S, et al. Roles of HDAC3-orchestrated circadian clock gene oscillations in diabetic rats following myocardial ischaemia/reperfusion injury[J]. Cell Death Dis, 2021, 12(1):43. doi:10.1038/s41419-020-03295-y.
[11]	PAUKLIN P, ZILMER M, EHA J, et al. Markers of inflammation,oxidative stress,and fibrosis in patients with atrial fibrillation[J]. Oxid Med Cell Longev, 2022, 2022:4556671. doi:10.1155/2022/4556671.
[12]	ZHANG M, YANG X, ZIMMERMAN R J, et al. CaMKII exacerbates heart failure progression by activating class I HDACs[J]. J Mol Cell Cardiol, 2020, 149:73-81. doi:10.1016/j.yjmcc.2020.09.007.
[13]	YUE Z, ZHANG Y, ZHANG W, et al. Kaempferol alleviates myocardial ischemia injury by reducing oxidative stress via the HDAC3-mediated Nrf2 signaling pathway[J]. J Adv Res, 2025, 75:755-764. doi:10.1016/j.jare.2024.10.037.
[14]	GUO X, HONG S, HE H, et al. NFκB promotes oxidative stress-induced necrosis and ischemia/reperfusion injury by inhibiting Nrf2-ARE pathway[J]. Free Radic Biol Med, 2020, 159:125-135. doi:10.1016/j.freeradbiomed.2020.07.031.
[15]	BELL J A, DAVIES E R, BRERETON C J, et al. Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2[J]. Cell Rep Med, 2024, 5(9):101695. doi:10.1016/j.xcrm.2024.101695.
[16]	PENG L, SUN W, CHENG D, et al. NUDT21 regulates lysyl oxidase-like 2(LOXL2) to influence ECM protein cross-linking in silica-induced pulmonary fibrosis[J]. Ecotoxicol Environ Saf, 2025, 290:117572. doi:10.1016/j.ecoenv.2024.117572.
[17]	邢佳侬, 梁卓, 邢爱君, 等. LncRNA MIAT靶向调节miR-128-3p对心房颤动大鼠心室重构和心肌纤维化的影响[J]. 天津医药, 2022, 50(9):932-937.
	XING J N, LIANG Z, XING A J, et al. Effects of lncRNA MIAT on ventricular remodeling and myocardial fibrosis in rats with atrial fibrillation through targeting regulation of miR-128-3p[J]. Tianjin Med J, 2022, 50(9):932-937. doi:10.11958/20220015.
[18]	ZHU Z. Serum LOXL2 is elevated and an independent biomarker in patients with coronary artery disease[J]. Int J Gen Med, 2024, 17:4071-4080. doi:10.2147/IJGM.S478044.
[19]	LUO J, WU Y, ZHU X, et al. LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway[J]. Iran J Basic Med Sci, 2022, 25(8):964-969. doi:10.22038/IJBMS.2022.63338.13981.
[20]	王岳胜, 刘晓晨, 刘恩香, 等. 持续性心房颤动患者血清miR-133a-3p和miR-324-3p表达与射频消融术后房颤复发的关系[J]. 现代检验医学杂志, 2024, 39(6):108-112,118.
	WANG Y S, LIU X C, LIU E X, et al. Relationship between the expressions of serum miR-133a-3p and miR-324-3p in patients with persistent atrial fibrillation and the recurrence of atrial fibrillation after radiofrequency ablation[J]. J Mod Lab Med, 2024, 39(6):108-112,118. doi:10.3969/j.issn.1671-7414.2024.06.018.

组别	n		年龄/ 岁	性别/ （男/女）		BMI/ （kg/m²）		吸烟史		饮酒史
健康组	132		51.32±7.16	78/54		22.96±1.16		47（35.61）		34（28.03）
疾病组	200		52.57±7.15	123/77		23.21±1.20		75（37.50）		55（27.50）
t或χ²			1.561	0.193		1.875		0.123		0.123
组别		心率/（次/min）			基础疾病
组别		心率/（次/min）			高血压		糖尿病		冠心病
健康组		95.12±3.44			50（37.88）		23（17.42）		20（15.15）
疾病组		95.06±3.54			97（48.50）		48（24.00）		37（18.50）
t或χ²		0.169			3.636		2.045		0.627

组别	n		年龄/ 岁	性别/ （男/女）		BMI/ （kg/m²）		吸烟史		饮酒史
健康组	132		51.32±7.16	78/54		22.96±1.16		47（35.61）		34（28.03）
疾病组	200		52.57±7.15	123/77		23.21±1.20		75（37.50）		55（27.50）
t或χ²			1.561	0.193		1.875		0.123		0.123
组别		心率/（次/min）			基础疾病
组别		心率/（次/min）			高血压		糖尿病		冠心病
健康组		95.12±3.44			50（37.88）		23（17.42）		20（15.15）
疾病组		95.06±3.54			97（48.50）		48（24.00）		37（18.50）
t或χ²		0.169			3.636		2.045		0.627

时期	HDAC3/（μg/L）	LOXL2/（ng/L）
术前	8.64±1.16	148.35±14.92
术后	6.21±1.05	127.79±15.16
t	21.731^＊＊	13.984^＊＊

时期	HDAC3/（μg/L）	LOXL2/（ng/L）
术前	8.64±1.16	148.35±14.92
术后	6.21±1.05	127.79±15.16
t	21.731^＊＊	13.984^＊＊

组别		n		年龄/岁			性别/ （男/女）			BMI/ （kg/m²）			吸烟史	饮酒史			心率/ （次/min）		基础疾病
组别		n		年龄/岁			性别/ （男/女）			BMI/ （kg/m²）			吸烟史	饮酒史			心率/ （次/min）		高血压			糖尿病			冠心病
未复发组		125		52.15±7.24			69/56			23.18±1.13			45（36.00）	35（28.00）			94.96±3.45		56（44.80）			28（22.40）			22（17.60）
复发组		75		53.28±7.37			54/21			23.25±1.26			30（40.00）	20（26.67）			95.49±3.78		41（54.67）			20（26.67）			15（20.00）
t或χ²				1.060			5.588^＊			0.463			0.320	0.042			0.996		1.827			0.468			0.179
组别			病程/年			NYHA心功能分级									QT值/ms			QTc值/ms			LVEDD/mm			LVESD/mm
组别			病程/年			Ⅰ级			Ⅱ级			Ⅲ级			QT值/ms			QTc值/ms			LVEDD/mm			LVESD/mm
未复发组			3.98±1.52			51（40.80）			58（46.40）			16（12.80）			405.24±20.15			422.15±20.24			50.12±4.85			35.24±4.92
复发组			4.53±1.68			20（26.67）			28（37.33）			27（36.00）			408.35±21.24			427.59±21.35			50.98±5.12			36.15±5.08
t或χ²			2.412^＊			15.269^＊＊									1.036			1.802			1.189			1.237
组别	LAD/mm				LVEF			TC/（mmol/L）			TG/（mmol/L）					HDL-C/（mmol/L）		LDL-C/（mmol/L）		HDAC3/（μg/L）			LOXL2/（ng/L）
未复发组	40.25±4.75				0.59±0.05			4.72±0.52			1.72±0.36					1.29±0.14		2.65±0.53		5.67±1.11			120.37±14.95
复发组	47.83±5.05				0.54±0.05			4.80±0.55			1.79±0.40					1.27±0.13		2.76±0.55		7.12±1.02			140.16±14.70
t或χ²	10.653^＊＊				6.267^＊＊			1.032			1.293					0.521		1.272		9.111^＊＊			9.121^＊＊